The Uncharted Architecture of Atherosclerosis: Beyond Lipid Panels — Functional Subspecies, Risk Stratification, and Targeted Therapy

 

Prefatory Note — On Levels of Resolution

This note serves as the conceptual introduction to the book. It explains the levels of resolution through which the reader will move and how they fit together into a single architecture of disease.

Every mature science passes through the same turning point. It begins by measuring what it can see, and only later discovers that the decisive structure lies beneath the surface of those measurements.

Chemistry measured atomic weights and valence long before it understood electron shells. Blood pressure was a useful number in medicine decades before arterial wall biology was understood. In lipid medicine, we have measured total cholesterol, LDL‑C, HDL‑C, and triglycerides for generations, yet have known remarkably little about what these numbers actually contain in structural and functional terms.

This book is written at that turning point.

From surface numbers to hidden structure

The conventional lipid panel is not wrong. It is a necessary, low‑resolution view of a high‑resolution reality. A total cholesterol value, or an LDL‑C concentration, is like an atomic weight on an early chemist’s table: measurable, reproducible, and often predictive, yet blind to the configuration that ultimately determines behavior.

Physics offers a useful language for this problem.

• Classical chemistry works with atomic weights and simple formulas.
• Atomic physics goes deeper, to electron configuration.
• Nuclear physics looks inside the nucleus itself, where a small change in configuration can transform a stable isotope into a radioactive one.

At each step, measurement moves closer to the hidden structure that governs outcomes. Crucially, the deeper levels do not discard the earlier ones. Atomic weights remain valid; they are simply embedded in a richer framework.

A similar hierarchy exists in lipid biology:

• At the “classical chemistry” level, we see total cholesterol and broad fractions like LDL‑C and HDL‑C.
• At the “atomic” level, we can describe lipoprotein subclasses and apoB as structural carriers.
• At the “nuclear” level, we encounter what this book will call functional subspecies: lipoprotein populations within a nominal class that differ in size, oxidation state, retention behavior, receptor interaction, and inflammatory signaling.
• At the “nuclear reaction” level, we meet plaque stability, cap rupture, thrombosis, and the explosive transition from silent disease to clinical catastrophe.

Physics did not stop at nuclear structure. The Standard Model describes quarks, leptons, and force‑carrying bosons that underlie nuclear behavior. In atherosclerosis, an analogous “elementary particle” level is emerging in the form of single‑cell biology, clonal smooth muscle expansion, immune cell phenotypes, and omics‑defined plaque micro‑states. We are not yet ready to build clinical algorithms from that level, but a complete architecture must leave room not only for this future resolution, but also for layers that remain unknown today.

The central claim of this book is that atherosclerosis can only be fully understood—and rationally treated—when this higher‑resolution architecture of functional subspecies, plaque structure, and emerging cellular micro‑states is integrated with the familiar, lower‑resolution measures that have guided practice to date. The basic panel remains useful; it becomes one layer in a multi‑layer description rather than the whole story.

Levels of resolution in this book

The chapters that follow are organized explicitly by levels of resolution. The same disease process is viewed repeatedly from different distances, with the reader’s “magnification” always made clear.

At some points, the lens is wide. We look at population risk, age, sex, inheritance, and familiar clinical categories. At other points, the lens is tight. We examine the behavior of apoB‑containing particles in the arterial wall, the structural peculiarities of Lp(a), or the conditions under which an otherwise stable plaque loses its integrity. Later chapters point toward the still‑deeper cellular and molecular landscape that current clinical tools can see only in outline.

This design serves two purposes:

1. To keep the reader oriented: you will always know which level of the system is under discussion.
2. To show that many apparent contradictions in the literature arise from mixing levels—and that they dissolve when dietary exposure, hereditary machinery, inflammatory state, plaque structure, and cellular micro‑biology are each seen in their proper frame and then recombined.

The title of this book, The Uncharted Architecture of Atherosclerosis, is meant quite literally. The “architecture” refers to the layered organization of lipid transport, arterial retention, inflammatory response, repair, failure, and the cellular and molecular states that underlie them. It is “uncharted” not because nothing is known, but because current practice still relies heavily on surface numbers that do not fully map the underlying design.

Disturbed lipid homeokinesis as the substrate

A recurring term in these pages is disturbed lipid homeokinesis. By this we mean not a static imbalance, but a long‑running failure of dynamic regulation: synthesis, packaging, transport, retention, receptor handling, clearance, and cellular processing of atherogenic lipoproteins.

Homeokinesis emphasizes motion rather than equilibrium. Healthy arterial biology depends on continuous adjustment and compensation in response to changing internal and external conditions. When this adaptive regulation begins to fail—because of inherited defects, acquired metabolic stress, inflammatory signals, endocrine transitions, organ dysfunction, or combinations of these—the system enters a trajectory in which arterial lipid burden accumulates, repair mechanisms falter, and structural failure becomes more likely over time.

Within that disturbed dynamic, the functional subspecies of lipoproteins—different “isotopes” within the same class—play a decisive role. Two patients may have similar LDL‑C values, yet carry very different subspecies profiles and therefore very different risks. One may have a predominance of particles that are readily cleared and relatively inert. The other may carry particles that penetrate, lodge, oxidize, and inflame. The standard panel cannot see this difference, but the artery can.

A discipline of evidence: three tiers

Because this book moves between clinical observation, mechanistic reasoning, and forward‑looking hypothesis, it must be explicit about the status of its claims. The discussion is therefore guided throughout by a three‑tier epistemic discipline:

• Established: Findings supported by convergent lines of evidence from epidemiology, mechanistic studies, and clinical trials—for example, the central role of apoB‑containing lipoproteins in atherogenesis and the causal contribution of Lp(a) to cardiovascular risk.
• Emerging: Patterns strongly suggested by current data but not yet fully resolved, often because trials are ongoing, observational evidence is still accumulating, or mechanistic work is incomplete. Some forms of Lp(a) modulation and the impact of specific inflammatory states fall here.
• Hypothetical: Proposals that are biologically plausible and internally coherent, but that lack direct empirical confirmation—such as deeper forms of acquired remodeling, including the possibility that viral injury, chronic inflammation, or progenitor‑cell reprogramming might induce more durable changes in lipoprotein expression over the life course.

Whenever the book speaks about mechanisms, especially in domains where randomized trials are incomplete or absent, the reader will be told which tier is in play. Nowhere is this more important than in the chapters on Lp(a), viral and inflammatory influences on lipid‑regulating machinery, and the long‑term biology of acquired expression layered on inherited substrate.

Mechanistic thinking is indispensable for making sense of complex disease, but mechanism without empirical discipline can mislead. Conversely, trial data without a coherent structural model can be hard to integrate. The aim here is to hold both sides together: a clear architecture of ideas, and a constant acknowledgment of where that architecture rests on rock and where it still rests on scaffolding.

How to read this book

Readers may come to this volume with different primary questions:

• A clinician may ask why two patients with similar lipid panels and lifestyles have dramatically different disease courses.
• A researcher may ask how inherited disorders such as familial hypercholesterolemia or elevated Lp(a) illuminate the underlying machinery.
• A policy‑maker may ask how hereditary and acquired risk should shape prevention strategies across the life course.

The answer in each case requires a shift in resolution—and then a return to the whole.

If you read front‑to‑back, you will move from historical experiments and conceptual corrections, through the metabolic and structural substrate of disease, into hereditary patterns, acquired dysregulation, and finally to the clinical and therapeutic consequences. If you enter at specific points—for example, the chapters on Lp(a)‑targeted therapy or on life‑course prevention—you will find signposts back to the deeper levels of the architecture on which those clinical arguments rest.

The only consistent invitation is this: whenever an apparent contradiction arises—between diet and heredity, between LDL‑C and clinical events, between genetic stability and acquired change—ask first whether two different levels of resolution are being mixed. Often, when they are separated, examined, and then re‑connected in the right order, the contradiction dissolves.

This book is an attempt to provide that ordering, which is currently in progress and will be completed in the near future.

Mykola Iabluchanskyi, Vladimir Shlyakhover, 

Pavlo Garkaviy, Andriy Yabluchanskiy